 |
|
|
| |
The Nonsteroidal FXR Agonist GS-9674 Leads to Significant Reductions in Hepatic Steatosis, Serum Bile Acids, and Liver Biochemistry in a Phase 2, Randomized, Placebo-Controlled Trial of Patients With NASH
|
| |
| |
Reported by Jules Levin
AASLD 2018 Nov 9-13 San Francisco
Keyur Patel,1 Stephen A. Harrison,2 James F. Trotter,3 Robert Herring,4 Sergio Rojter,5 Zeid Kayali,6 Mitchell L. Shiffman,7 Bradley Freilich,8 Eric J. Lawitz,9 Eliza Harting,10 Tuan Nguyen,10 Chuhan Chung,10 G. Mani Subramanian,10 Robert P. Myers,10 Michael S. Middleton,11 Mary Rinella,12 Mazen Noureddin13
1University of Toronto, Ontario, Canada; 2Pinnacle Research, San Antonio, TX; 3Texas Digestive Disease Consultants, Dallas, TX; 4Quality Medical Research, PLLC, Nashville, TN; 5Ruane Clinical Research Group, Inc., Los Angeles, CA; 6Inland Empire Liver Foundation, Rialto, CA; 7Bon Secours Liver Institute of Richmond, VA; 8Kansas City Research Institute, Kansas City, MO; 9Texas Liver Institute, UT Health San Antonio; 10Gilead Sciences, Inc., Foster City, CA; 11UC San Diego, La Jolla, CA; 12Feinberg School of Medicine, Northwestern University, Chicago, IL; 13Cedars-Sinai Medical Center, Los Angeles
|
| |
|
|
|
|
|
